The analyst report update initiative was triggered by KALY’s recent CEO update on the company’s cannabis extract biopharmaceutical business.
Read More
The company has been working with world renowned PHD scientist and seven time Nobel Peace Prize nominee to develop this line of proprietary CBD and probiotic powder formulations.
Read More
KALY Develops COPD Treatment CBD Formulation from Its Patented Extraction Process.
Read More
The company is currently developing Cannabis Extract Biopharmaceutical Therapies targeting $170 billion in market potential.
Read More
This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS).
Read More
Get stock alerts, news & related alerts straight to your inbox!